TWiV 1052: Clinical update with Dr. Daniel Griffin

October 14, 2023

In his weekly clinical update, Dr. Griffin discusses disease severity of RSV compared with COVID-19 and Influenza among hospitalized adults aged ≥60 years, antiviral efficacy of Molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19, Nirmatrelvir-Ritonavir and COVID-19 mortality and hospitalization among patients with vulnerability to covid-19 complications, antibiotic use among hospitalized patients with COVID-19 in the United States, one week of oral Camostat vs Placebo in nonhospitalized adults with mild-to-moderate COVID-19, assessment of the available therapeutic approaches for severe COVID-19, optimal duration of systemic Corticosteroids in COVID-19 treatment, effect of monovalent COVID-19 vaccines on viral interference between SARS-CoV-2 and several DNA viruses in patients with long-COVID syndrome, local budesonide therapy in the management of persistent hyposmia in suspected non-severe COVID-19 patients, and the safety profile and clinical and virological outcomes of Nirmatrelvir-Ritonavir treatment in patients with advanced chronic Kidney disease and COVID-19.

Click arrow to play
Download TWiV 1052 (32 MB .mp3, 45 min)

Subscribe (free): Apple PodcastsGoogle PodcastsRSSemail

Become a patron of TWiV!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to

Leave a Reply

Your email address will not be published. Required fields are marked *